Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | June 05, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 74,497 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 74,497 · Balance 74,497 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
RECURSION PHARMACEUTICALS, INC.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 883,735 |
Ending reported balance
After 2026-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-05 · Conversion · Acquired 40,000 · Balance 923,735 F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock. F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. Row 2 · 2026-06-05 · Sale · Disposed 40,000 · Balance 883,735 F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,263,334 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Conversion · Disposed 40,000 · Balance 4,263,334 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock. F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby LAHWRAN-3 LLC | 386,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 386,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby LAHWRAN-4 LLC | 388,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 388,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F5: The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager. |
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Indirectby Gibson Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 50,000 F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2035-02-03 | Direct | 1,050,567 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 1,050,567 F7: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.09 · Expires 2034-02-09 | Direct | 666,898 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 666,898 F8: The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2033-02-01 | Direct | 813,600 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 813,600 F9: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 399,002 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 399,002 F10: The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2032-02-04 | Direct | 5,436 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 5,436 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2030-12-30 | Direct | 282,500 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 282,500 F11: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a sale of the shares by the Reporting Person. Each share of Class B Common Stock is convertible into one share of Class A Common Stock.
F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
F3: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F4: The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F5: The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F6: The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
F7: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F8: The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F9: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F10: The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F11: The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2022 Filed Feb 25, 2022 00:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012844 · doc4.xml · derivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,658,484 Underlying: Class A Common Stock · 7,658,484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. F2 · price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 100,000 | $10.22 | $1,021,540.00 |
DisclosureSEC source: 0001209191-22-012844 · doc4.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,020 F3 · kind: Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral. F4 · price: This transaction was executed in multiple trades at prices ranging from $9.91 to $10.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012844 · doc4.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. F2 · price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 5,436 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007909 · doc4.xml · derivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,436 Underlying: Class A Common Stock · 5,436 shares Expires 2032-02-04 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 416,350 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001209191-22-007909 · doc4.xml · derivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,350 Underlying: Class A Common Stock · 416,350 shares Expires 2032-02-04 F3 · derivative.exercise_date: The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 343 | $11.40 | $3,910.20 |
DisclosureSEC source: 0001209191-22-007909 · doc4.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,020 Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 2,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007909 · doc4.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,363 F2 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 04, 2022 Filed Feb 9, 2022 02:03 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 208,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007909 · doc4.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,645 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 19,858 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006596 · doc4.xml · derivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,758,484 Underlying: Class A Common Stock · 19,858 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 19,858 | $11.73 | $232,964.13 |
DisclosureSEC source: 0001209191-22-006596 · doc4.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F2 · kind: Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral. F3 · price: This transaction was executed in multiple trades at prices ranging from $11.43 to $11.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 01:09 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 19,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006596 · doc4.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. Read SEC document |
| January 14, 2022 Filed Jan 15, 2022 01:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 254,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003402 · doc4.xml · derivative · entry 8 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,778,342 Underlying: Class A Common Stock · 254,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| January 14, 2022 Filed Jan 15, 2022 01:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 254,000 | $13.57 | $3,445,611.60 |
DisclosureSEC source: 0001209191-22-003402 · doc4.xml · nonDerivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F2 · kind: Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral. F5 · price: This transaction was executed in multiple trades at prices ranging from $13.09 to $14.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 14, 2022 Filed Jan 15, 2022 01:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 254,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003402 · doc4.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. Read SEC document |
| January 13, 2022 Filed Jan 15, 2022 01:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 87,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003402 · doc4.xml · derivative · entry 7 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,032,342 Underlying: Class A Common Stock · 87,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| January 13, 2022 Filed Jan 15, 2022 01:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 8,794 | $14.96 | $131,574.95 |
DisclosureSEC source: 0001209191-22-003402 · doc4.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F2 · kind: Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral. F4 · price: This transaction was executed in multiple trades at prices ranging from $14.80 to $15.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 13, 2022 Filed Jan 15, 2022 01:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 78,206 | $14.26 | $1,114,990.76 |
DisclosureSEC source: 0001209191-22-003402 · doc4.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,264 F2 · kind: Shares were sold by a lender to the Reporting Person to satisfy a margin call related to a loan in which the shares served as collateral. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.80 to $14.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 13, 2022 Filed Jan 15, 2022 01:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 87,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003402 · doc4.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. Read SEC document |
| January 05, 2022 Filed Apr 28, 2023 20:32 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 18,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026045 · doc4a.xml · derivative · entry 33 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,601,834 Underlying: Class A Common Stock · 18,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. F6 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| January 05, 2022 Filed Apr 28, 2023 20:32 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 18,500 | $7.39 | $136,668.75 |
DisclosureSEC source: 0001209191-23-026045 · doc4a.xml · nonDerivative · entry 22 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 582,805 F1 · kind: Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $7.29 to $7.71. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| January 05, 2022 Filed Apr 28, 2023 20:32 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026045 · doc4a.xml · nonDerivative · entry 21 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 601,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. Read SEC document |
| December 28, 2021 Filed Jan 15, 2022 01:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass B Common Stock · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003402 · doc4.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,119,342 Underlying: Class A Common Stock · 75,000 shares Expires not disclosed F6 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F6 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 22:59 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 200 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070627 · doc4.xml · derivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,194,342 Underlying: Class A Common Stock · 200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. F4 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F4 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 22:59 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 200 | $20.01 | $4,001.00 |
DisclosureSEC source: 0001209191-21-070627 · doc4.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2021 Filed Dec 20, 2021 22:59 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070627 · doc4.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069853 · doc4.xml · derivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,194,542 Underlying: Class A Common Stock · 100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. F3 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 100 | $20.02 | $2,001.50 |
DisclosureSEC source: 0001209191-21-069853 · doc4.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:01 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069853 · doc4.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 1,086 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · derivative · entry 9 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,194,642 Underlying: Class A Common Stock · 1,086 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. F8 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F8 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F9 · balance_after: Shares of Class B Common Stock held directly and indirectly by the Reporting Person were previously reported in Table I of Forms 4 filed by the Reporting Person. Commencing with this Form 4, shares of Class B Common Stock held directly and indirectly by the Reporting Person are to be reported in Table II of Form 4. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,086 | $20.01 | $21,729.88 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · nonDerivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 09, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 1,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · nonDerivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass B Common Stock · Derivative | 5,488 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · derivative · entry 8 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,195,728 Underlying: Class A Common Stock · 5,488 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. F8 · derivative.exercise_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F8 · derivative.expiration_date: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F9 · balance_after: Shares of Class B Common Stock held directly and indirectly by the Reporting Person were previously reported in Table I of Forms 4 filed by the Reporting Person. Commencing with this Form 4, shares of Class B Common Stock held directly and indirectly by the Reporting Person are to be reported in Table II of Form 4. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,646 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · derivative · entry 7 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,471,354 Underlying: Class A Common Stock · 28,646 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: The option, originally for 1,500,000 shares, of which 28,646 shares have been exercised, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. F7 · derivative.underlying: This option, originally reported in the Reporting Person's Form 3 as exercisable for Class B Common Stock, is in fact exercisable for Class A Common Stock. Upon exercise of the option, the Reporting Person has the right to require the Issuer to exchange any such shares of Class A Common Stock for a number of Class B Common Stock of equivalent value. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 5,488 | $20.26 | $111,162.18 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.57. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionClass A Common Stock | 5,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · kind: Represents the conversion of Class B Common Stock into Class A Common Stock. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 5,176 | $20.03 | $103,670.10 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: This transaction, representing a sale to cover the exercise price and related tax withholdings for 28,646 option shares, was executed in multiple trades at prices ranging from $20.014 to $20.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 08, 2021 Filed Dec 11, 2021 02:42 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Exercise / conversionClass A Common Stock | 28,646 | $2.47 | $70,755.62 |
DisclosureSEC source: 0001209191-21-069159 · doc4.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass B Common Stock | 100 | $21.07 | $2,107.00 |
DisclosureSEC source: 0001209191-21-068922 · doc4.xml · nonDerivative · entry 7 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Gibson Family Trust Disclosed balance after: 146,875 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass B Common Stock | 3,025 | $20.49 | $61,993.75 |
DisclosureSEC source: 0001209191-21-068922 · doc4.xml · nonDerivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Gibson Family Trust Disclosed balance after: 146,975 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F4 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.07 to $21.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass B Common Stock | 1,200 | $21.06 | $25,266.96 |
DisclosureSEC source: 0001209191-21-068922 · doc4.xml · nonDerivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,201,216 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $21.02 to $21.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass B Common Stock | 15,467 | $20.43 | $316,065.05 |
DisclosureSEC source: 0001209191-21-068922 · doc4.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,202,416 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.01 to $20.99 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 21, 2021 Filed Dec 10, 2021 02:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass B Common Stock | 550,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-068922 · doc4.xml · nonDerivative · entry 3 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By LAHWRAN-4 LLC Disclosed balance after: 550,000 Read SEC document |
| November 21, 2021 Filed Dec 10, 2021 02:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass B Common Stock | 550,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-068922 · doc4.xml · nonDerivative · entry 2 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By LAHWRAN-3 LLC Disclosed balance after: 550,000 Read SEC document |
| November 21, 2021 Filed Dec 10, 2021 02:52 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GiftClass B Common Stock | 1,100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-068922 · doc4.xml · nonDerivative · entry 1 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,217,883 Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-21-028030 · doc4.xml · derivative · entry 9 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Class B Common Stock · 1,500,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 1,500,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-21-028030 · doc4.xml · derivative · entry 8 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2030-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries A-1 Preferred Stock · Derivative | 32,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028030 · doc4.xml · derivative · entry 7 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,685 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSerie A Preferred Stock · Derivative | 22,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028030 · doc4.xml · derivative · entry 6 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the "Issuer") initial public offering of Class A Common Stock (the "IPO"). Each shares of Series C Preferred Stock automatically converted into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's IPO. The right to convert Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock into Common Stock had no expiration date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass B Common Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028030 · doc4.xml · nonDerivative · entry 5 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Gibson Family Trust Disclosed balance after: 150,000 F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 23:57 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028030 · doc4.xml · nonDerivative · entry 4 Gibson Christopher · CIK 0001856369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Gibson Family Trust Disclosed balance after: 0 F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.